A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

NCT06471673 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Tumor
Cancer of Breast
Cancer of the Breast
Malignant Tumor of Breast
Tumors, Breast

Interventions

BIOLOGICAL: BC1 cell line
BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab)
BIOLOGICAL: Bria-OTS regimen and CPI (tislelizumab) expansion cohort

Sponsor

BriaCell Therapeutics Corporation